Crossmark

Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of 68Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy

Crossref DOI link: https://doi.org/10.1007/s11307-021-01600-5

Published Online: 2021-04-07

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lodge, Martin A. https://orcid.org/0000-0003-0922-6519
Solnes, Lilja B.

Chaudhry, Muhammad A.

Wahl, Richard L.
License Information

Text and Data Mining valid from 2021-04-07

Version of Record valid from 2021-04-07
More Information

Article History

Received: 1 February 2021

Revised: 15 March 2021

Accepted: 29 March 2021

First Online: 7 April 2021

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below